News | September 15, 2022
AstraZeneca launches up-skilling program iPHARMACY
The company has partnered with Neethi, a Kerala state cooperative consumers federation limited company, to run this program in Kerala
The company has partnered with Neethi, a Kerala state cooperative consumers federation limited company, to run this program in Kerala
This will give a boost to cost-effective, quality medicines and contribute towards reduction in out of pocket expenditure on healthcare for the citizens
The reliability of their products, evidenced by their inclusion in the WHO emergency use list, has further improved with the addition of Takara Bio's enzymes.
This association between the two esteemed organizations allows Medvarsity to significantly – and positively – impact healthcare education
If implemented across the world, it has the capability to save over 100,000 lives annually
Japan’s Ministry of Health, Labour and Welfare (MHLW) has recently approved AstraZeneca's long-acting antibody combination “Evusheld” for the prevention ) and treatment of COVID-19.
Results demonstrated a 64.5% confirmed objective response rate in patients treated with investigational combination of enfortumab vedotin and pembrolizumab
Findings to be featured in a late-breaking proffered paper session at European Society for Medical Oncology (ESMO) Congress 2022
In first-line metastatic NSCLC, KEYTRUDA-based regimens have now shown a five-year survival benefit in four trials
The Phase 3 SOLO-1 trial demonstrated 67% of advanced ovarian cancer patients with BRCA mutations receiving LYNPARZA were alive at seven years versus 47% of placebo patients
Subscribe To Our Newsletter & Stay Updated
